JP2023533768A5 - - Google Patents

Info

Publication number
JP2023533768A5
JP2023533768A5 JP2023501609A JP2023501609A JP2023533768A5 JP 2023533768 A5 JP2023533768 A5 JP 2023533768A5 JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023533768 A5 JP2023533768 A5 JP 2023533768A5
Authority
JP
Japan
Prior art keywords
specific binding
binding molecule
fragment
nucleic acid
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501609A
Other languages
English (en)
Japanese (ja)
Other versions
JP7796719B2 (ja
JP2023533768A (ja
Filing date
Publication date
Priority claimed from GBGB2010652.2A external-priority patent/GB202010652D0/en
Application filed filed Critical
Publication of JP2023533768A publication Critical patent/JP2023533768A/ja
Publication of JP2023533768A5 publication Critical patent/JP2023533768A5/ja
Application granted granted Critical
Publication of JP7796719B2 publication Critical patent/JP7796719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501609A 2020-07-10 2021-07-09 抗タウ抗体 Active JP7796719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010652.2 2020-07-10
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (3)

Publication Number Publication Date
JP2023533768A JP2023533768A (ja) 2023-08-04
JP2023533768A5 true JP2023533768A5 (enExample) 2024-05-09
JP7796719B2 JP7796719B2 (ja) 2026-01-09

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501609A Active JP7796719B2 (ja) 2020-07-10 2021-07-09 抗タウ抗体

Country Status (10)

Country Link
US (1) US12624096B2 (enExample)
EP (1) EP4178980A1 (enExample)
JP (1) JP7796719B2 (enExample)
KR (1) KR20230038721A (enExample)
CN (1) CN116194479B (enExample)
AU (1) AU2021306653A1 (enExample)
CA (1) CA3185175A1 (enExample)
GB (1) GB202010652D0 (enExample)
TW (1) TWI912331B (enExample)
WO (1) WO2022008719A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
KR101231777B1 (ko) 2010-11-25 2013-02-08 부산대학교 산학협력단 GSK3β 저해를 통한 타우 과인산화 저해제 탐색 방법
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Similar Documents

Publication Publication Date Title
JP2018524001A5 (enExample)
NZ748983A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2022541539A5 (enExample)
JP2023113696A5 (enExample)
JP7109467B2 (ja) タウに特異的に結合する結合分子
RU2019118922A (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP2018531580A5 (enExample)
JP2013524774A5 (enExample)
JP2018519810A5 (enExample)
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2021524267A5 (enExample)
JP2018505651A5 (enExample)
JP2020513804A5 (enExample)
JP2011528901A5 (enExample)
IL266911B1 (en) Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
JP2013525266A5 (enExample)
JP2020529473A5 (enExample)
JP2023071956A5 (enExample)
FI3303386T3 (fi) Tau-vasta-aineita ja käyttömenetelmiä
JP2020513791A5 (enExample)
US20220273779A1 (en) Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
JP2013500940A5 (enExample)
JP2018535650A5 (enExample)
JP2018516853A5 (enExample)
JP2017532288A5 (enExample)